PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA). Background: Standard dose radiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results